Global Age-Related Macular Degeneration (AMD) Disease - Anti VEGF Market
The global Age-Related Macular Degeneration (AMD) Disease - Anti VEGF market is estimated to be worth over USD23.87 Bn in 2033 and is expected to grow at CAGR of3.9% during the forecast period (2024-2033).
The global Anti-VEGF (Vascular Endothelial Growth Factor) market targeting Age-Related Macular Degeneration (AMD) disease is marked by substantial growth and innovation fuelled by numerous key factors. The leading driving force behind the market's expansion is the growing prevalence of AMD, a primary cause of vision impairment and blindness among older adults. Since populations age and lifestyles change, the incidence of AMD surges, requiring effective treatments to preserve vision and improve patient outcomes. Anti-VEGF therapies have emerged as a standard of care for wet AMD, impeding abnormal blood vessel growth beneath the retina and slowing disease progression. Significant pharmaceutical companies offer Anti-VEGF drugs such as ranibizumab (Lucentis), aflibercept (Eylea), and bevacizumab (Avastin), which are administered via intravitreal injections and have demonstrated efficiency in enhancing visual acuity and mitigating the risk of vision loss in patients with wet AMD.
Major developments in the market compriseprogressions in drug formulations and sustained-release delivery systems, enabling for extended dosing intervals and lessened treatment burden. These innovations improve patient convenience and adherence while optimizing treatment outcomes. In addition to that, combination therapies involving Anti-VEGF drugs and other agents, such as steroids or angiogenesis inhibitors, are being explored to improve treatment efficiency and address diverse pathophysiological mechanisms underlying AMD.
New technologies also hold an essential role in spurring the market forward, with continuous research emphasizing on enhancinganti-VEGF therapies and developing next-generation treatments with enhanced efficacy and safety profiles. Gene therapy and gene editing approaches hold commitment for addressing the underlying mechanisms of AMD, providing long-term therapeutic benefits. Along with that, the integration of artificial intelligence (AI) and machine learning algorithms into diagnostic and treatment algorithms improves precision medicine approaches and facilitates personalized care for patients with AMD.
Overall, the global Anti-VEGF market for AMD stands ready for sustained growth and innovation, driven by increasing prevalence of AMD, advancements in drug development and delivery technologies, and ongoing research efforts to improve treatment outcomes and patient care. These factors collectively contribute to the market's expansion and highlight the significance of continued investment and innovation in AMD management.
The market report presents an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this industry, across different geographies. Amongst other elements, the market report includes:
A preface providing an introduction to the full report, Age-Related Macular Degeneration (AMD) Disease - Anti VEGFmarket, 2023-2033.
An outline of the systematic research methodology adopted to conduct the study on Age-Related Macular Degeneration (AMD) Disease - Anti VEGFmarket, providing insights on the various assumptions, methodologies, and quality control measures employed to ensure accuracy and reliability of our findings.
An overview of economic factors that impact the overall Age-Related Macular Degeneration (AMD) Disease - Anti VEGFmarket, including historical trends, currency fluctuation, foreign exchange impact, recession, and inflation measurement.
An executive summary of the insights captured during our research, offering a high-level view of the current state of the Age-Related Macular Degeneration (AMD) Disease - Anti VEGFmarket and its likely evolution in the mid-to-long term.
A brief introduction to the Age-Related Macular Degeneration (AMD) Disease - Anti VEGF, highlighting their historical background, as well as information on their types, key aspects, key challenges and the advantages of using Age-Related Macular Degeneration (AMD) Disease - Anti VEGF.
A detailed assessment of the market landscape of Age-Related Macular Degeneration (AMD) Disease - Anti VEGFthat are either approved or being evaluated in different stages of development, based on several relevant parameters, such as By Product (Eylea, Lucentis, Beovu), By Distribution Channel (Hospitals, Speciality Clinics, Mail Order Pharmacies). Further, the chapter features analysis on key niche market segments. In addition, the chapter features analysis of various Age-Related Macular Degeneration (AMD) Disease - Anti VEGFdevelopers, based on their year of establishment, company size, location of headquarters and most active players.
An in-depth analysis of partnerships and collaborations that have been inked between various stakeholders, since 2019, based on several relevant parameters, such as the year of partnership, type of partnership, focus of partnership, purpose of partnership, therapeutic applications and most active players (in terms of number of partnerships). It also highlights the regional distribution of partnership activity in this market.
A detailed analysis of various investments made by companies engaged in this industry, since 2019, based on several relevant parameters, such as year of funding, type of funding (grants, seed, venture capital, initial public offering, secondary offerings, private equity and debt financing), type of HPAPIs, amount invested, geography, purpose of funding, stage of development, therapeutic area, most active players (in terms of number and amount of funding instances) and leading investors (in terms of number of funding instances).
An in-depth analysis of the various Age-Related Macular Degeneration (AMD) Disease - Anti VEGFfocused initiatives undertaken by big market players, based on several relevant parameters, such as number of initiatives, year of initiative, type of initiative, purpose of initiative, focus of initiative and location of headquarters of the big pharma players.
One of the key objectives of this market report was to estimate the current market size and the future growth potential of the Age-Related Macular Degeneration (AMD) Disease - Anti VEGFover the forecast period. Based on several parameters, such as regional analysis as well as segmental analysis rates, we have developed informed estimates of the likely evolution of the Age-Related Macular Degeneration (AMD) Disease - Anti VEGFmarket over the forecast period 2023-2033. Our year-wise projections of the current and future opportunity have further been segmented based on relevant parameters, such as By Product (Eylea, Lucentis, Beovu), By Distribution Channel (Hospitals, Speciality Clinics, Mail Order Pharmacies), by key geographical regions (North America, Europe, Asia-Pacific, Middle East and Africa, and South America) and leading players. In order to account for future uncertainties associated with some of the key parameters and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base, and optimistic scenarios, representing different tracks of the industry’s evolution.